Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%
- Check25 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%
- Check39 days agoChange DetectedRevision bumped from v3.0.1 to v3.0.2; removed 'Back to Top'. No substantive content changes detected.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has undergone significant updates, including the early termination of a study on Cabozantinib and Pembrolizumab for advanced metastatic melanoma, with new results reporting dates and changes in study design details. Key metrics such as overall survival and progression-free survival definitions have been clarified and updated.SummaryDifference16%
- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%
Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.